Skip to content

SOJF: Held by 2 Biotech Hedge Funds (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Sign In Start 14-Day Free Trial

Home›Companies›SOUTHERN CO (SOJF)

SOUTHERN CO

SOJF

Held by 2 specialist biotech funds

2 funds opened new positions.

Share

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

4.0/10

2 funds opened new positions

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

●●

No recent insider activity●●

No upcoming catalysts●●

Held by 2 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

Driehaus Capital

Eventide Asset ManagementHeld 7Q ↓

Position history (shares)

Driehaus Capital

6Q

Eventide Asset Management

7Q

AI Signal

Signal Note: Driehaus Growth Initiates SOJF Position

Growth-focused manager Michael Caldwell's $35.8M entry into Southern Company represents a notable pivot into utilities/infrastructure rather than a biotech thesis, contradicting the stated biotech allocation focus. Fund convergence with Eventide (also a specialist holder) suggests conviction on the energy transition narrative, though this appears to be a non-core position for a growth-oriented biotech PM and warrants clarification on strategic rationale.

Unlock full AI analysis — 14-day free trial

7 quarters

Position Trend

Aug 14, 2025

$123.0M

2 funds

Nov 14, 2025

$130.7M

2 funds

Feb 13, 2026

$9.7M

1 fund

Feb 17, 2026

$0

0 funds

-100% total institutional value over 15 quarters

Catalysts

No catalysts tracked.

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Position Details

Driehaus CapitalEXITFeb 17, 2026

Start free trialfor share counts, dollar values & AI analysis

20 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

VFC1 fund ZTS1 fund ZS1 fund EW1 fund ESI1 fund ADCT1 fund GPN1 fund TFC-PR1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: